Last reviewed · How we verify

NCT01757236: LIZ-BONE

Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive.

Status unknown Phase 2 Last updated 27 May 2014
What this trial tests

Phase 2 trial testing VANCOMYCIN in Hip Prosthetic Joint Infection in 100 participants. Status unknown.

Timeline
1 October 2012
Primary endpoint
1 April 2016
1 April 2016

Quick facts

Lead sponsorUniversity Hospital, Tours
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 October 2012
Primary completion1 April 2016
Estimated completion1 April 2016
Sites9 locations across France, Italy, Spain

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Tours

Who can join

Adults 18 to 80, any sex, with Hip Prosthetic Joint Infection. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of oral linezolid-rifampin combination therapy (over 4 or 6 weeks) versus the standard of care in the treatment of Gram-positive prosthetic hip joint infection with a one-stage surgical treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Tours trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01757236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing